Rhenman & Partners Asset Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Rhenman & Partners Asset Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-60,000	Closed	-$604K	–	95
2021 Q4	$604K	Hold	60,000	–	–	0.04%	92
2021 Q3	$2.04M	Hold	60,000	–	–	0.14%	87
2021 Q2	$2.2M	Hold	60,000	–	–	0.15%	92
2021 Q1	$2.69M	Hold	60,000	–	–	0.19%	90
2020 Q4	$3.42M	Buy	+60,000	New	+$3.56M	0.28%	73

Other funds holding DCPH

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Rhenman & Partners Asset Management's DCPH Position: Q1 2022 in Review

Rhenman & Partners Asset Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2022, closing a stake of 60,000 shares — an estimated $604K sold.

Rhenman & Partners Asset Management first reported a position in DCPH in Q4 2020 and held it in 5 quarters. The position peaked at $3.42M in Q4 2020. 123 funds tracked by Wall St. Rank hold DCPH as of Q1 2022.

Rhenman & Partners Asset Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Rhenman & Partners Asset Management sold 60,000 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $604K.
Rhenman & Partners Asset Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Rhenman & Partners Asset Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $3.42M in Q4 2020.
123 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2022, filed 13 May 2022.